1 / 4

LC-MS Analysis of Myc-Interacting Proteins in Breast Cancer Cells

Detailed lists of Myc-interacting proteins in MCF7, LCC1, and LCC1 EGF-treated cells, with differential expressions noted. Clinical trials exploring trastuzumab benefits in Her2 low/negative breast cancer patients.

marylyna
Download Presentation

LC-MS Analysis of Myc-Interacting Proteins in Breast Cancer Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Table S1 Complete list of LC-MS myc interating protiens in the MCF7 cells, proteins highlighted in red are those differentially expressed from the LCC1 and LCC1 EGF treated cells.

  2. Supplemental Table S2 Complete list of LC-MS myc interating protiens in the LCC1 cells, proteins highlighted in red are those differentially expressed from the LCC1 EGF and MCF7 cells

  3. Supplemental Table S3 Complete list of LC-MS myc interating protiens in the LCC1 EGF treated cells, proteins highlighted in red are those differentially expressed from the LCC1 and MCF7 cells

  4. Supplemental Table S4 Clinical trials examining the potential benefit of trastuzumab in Her2 low/Her2 negative breast cancer patients

More Related